drugset
Drugs / GAd-209-FSP
last change 3 days ago re-read 3 minutes ago

GAd-209-FSP

also known as GAd20-209-FSPs · Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP

Vaccine

Developed for
colorectal carcinoma
Investigated by
National Cancer Institute (NCI)

Trials 1

today NCT05078866 · Ph 1/2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05078866 Nov 2022 → Apr 2025 overdue Lynch syndrome, colorectal carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GAd-209-FSP ClinicalTrials.gov intervention name — accepted as the source's own label NCT05078866 ↗
Known as GAd20-209-FSPs “adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP (GAd20-209-FSPs) (1 prime)” NCT05078866 ↗
Known as Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP “Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP” NCT05078866 ↗
Modality Vaccine “adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP” NCT05078866 ↗
Route Intramuscular “Patients receive GAd20-209-FSPs intramuscularly (IM) on day 1” NCT05078866 ↗